Key result
Reducing or stopping beta-blocking antiarrhythmics is linked to less frequent RVP versus non-beta-blocking drugs.
Why the study?
The impact of antiarrhythmic therapy on dual-chamber pacemaker parameters in patients with paroxysmal atrial fibrillation and tachycardia-bradycardia syndrome was not well studied.
Does adjustment of antiarrhythmic therapy reduce frequent right ventricular pacing in patients with paroxysmal atrial fibrillation and dual-chamber pacemakers?
Cohort (n=203)
Does adjustment of antiarrhythmic therapy reduce frequent right ventricular pacing in patients with paroxysmal atrial fibrillation and dual-chamber pacemakers?
In patients with dual-chamber pacemakers and tachycardia-bradycardia syndrome, reducing or discontinuing drugs with beta-blocking properties effectively minimizes frequent right ventricular pacing, which may prevent heart failure progression.
May support beta-blocker sparing antiarrhythmics to limit RV pacing in pacemaker patients; leaves open effects on HF outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Volovchenko et al. (2022) conducted a cohort in Paroxysmal atrial fibrillation and sick sinus syndrome or binodal disease (n=203). Antiarrhythmic therapy with beta-blocking effects vs. Antiarrhythmic therapy without beta-blocking effects was evaluated on Minimization of frequent right ventricular pacing (p=<0.001). Dose reduction or discontinuation of antiarrhythmic drugs with beta-blocking effects significantly reduced frequent right ventricular pacing compared to drugs without beta-blocking effects (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: